ArticleCureus2026
Biological Effects of an Isoquercetin-Containing Formulation in Preclinical Models of Skin Aging.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Skin aging involves oxidative stress, inflammation, extracellular matrix degradation, and glycation. Bioactive compounds targeting multiple pathways may offer mechanistic advantages in skin aging modulation. Objective This study aimed to evaluate the biological effects of a compound containing isoquercetin using preclinical in vitro and ex vivo skin models. Methods Five independent assays were conducted in human skin explants, reconstructed human epidermis enriched with peripheral blood mononuclear cells (PBMCs), and human dermal fibroblasts (HFF-1). NQO1 gene expression was quantified by quantitative real-time polymerase chain reaction (qRT-PCR). IL-6 and IL-8 levels were measured using cytometric bead array. UV radiation-induced oxidative stress was assessed by radical protein assays. Ki-67 and type I pro-collagen expression were evaluated by immunofluorescence. Antiglycation and deglycation activity were assessed through carboxymethyl-lysine (CML) quantification. Data were analyzed using Student's t-test or one-way ANOVA. Results The compound significantly increased NQO1 expression (+78%, p < 0.05) in human skin explants. In the inflammatory model, IL-6 and IL-8 levels were reduced by 45% and 50%, respectively (p < 0.001). UV radiation-induced oxidative protein markers were reduced (radical protection: 66.79%, p < 0.001). Ki-67 expression increased by 41.83% (p < 0.05), and type I pro-collagen synthesis increased 2.01-fold (p < 0.0001). In fibroblast models, antiglycation and deglycation assays demonstrated reductions in CML levels of 56.90% and 39.75%, respectively (p < 0.001). Conclusion In preclinical skin models, a compound containing isoquercetin significantly modulated oxidative stress, inflammatory response, collagen synthesis, and glycation pathways. Controlled clinical studies are required to determine whether these biological effects translate into measurable outcomes in human subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.